Male Hypogonadism Market Share, Trends & Forecast - 2022

1
Male Hypogonadism Market
Opportunities and Forecasts, 2014 - 2022
Pages 157 Published 2017
2
 
MALE HYPOGONADISM MARKET
Injectables held the largest market share in
2015. The launch of innovative injectables for
the treatment of hypogonadism in men and rise in
preference for injections of gonadotropin-releasin
g hormones over TRT gels other formulations are
expected to drive growth of this drug delivery
method. Shubhangi Bawakar
3
 
MALE HYPOGONADISM MARKET OVERVIEW

• Male Hypogonadism Market report, published by
  Allied Market Research forecasts that the global
  market was valued at 2,594 million in 2015, and
  is estimated to reach 3,233 million by 2022,
  growing at a CAGR of 3.1 from 2016 to 2022. 
• The pituitary disorders segment accounted for
  nearly half of the total market share in 2015,
  and is expected to maintain its dominance during
  analysis period as well.
• Male hypogonadism is a clinical condition in
  which testes cannot produce enough testosterone,
  resulting in decreased development of muscle
  mass, impaired growth of body hair, development
  of breast tissues, and lack of deepening of the
  voice. 
• Growth in the male hypogonadism market is driven
  by the rise in prevalence incidence of men with
  testosterone deficiency, increase in infertility
  rates, and growth in awareness among the patient
  population about hypogonadism treatment options
  by certain campaigns carried out by the
  government. 
• Read more at https//www.alliedmarketresearch.co
  m/male-hypogonadism-market

4
PERCENTAGE OF TOTAL POPULATION AGED 65 YEARS
ABOVE BY COUNTRY
 
5
 
MALE HYPOGONADISM MARKET KEY BENEFITS

• The study provides an in-depth analysis of the
  market with current trends and future estimations
  to elucidate the imminent investment pockets.
• It presents a quantitative analysis from 2014 to
  2022, which is expected to enable the
  stakeholders to capitalize on prevailing market
  opportunities.
• Extensive analysis by therapy helps in
  understanding the various types of therapies used
  to treat hypogonadism.
• Comprehensive analysis of all geographical
  regions is provided, which assist in determining
  the main opportunities in these geographies.
• Key players within the market are profiled and
  their strategies are analyzed thoroughly to
  determine the competitive outlook of the global
  market.

6
 
MEXICO MALE HYPOGONADISM MARKET REVENUE
7
 
MALE HYPOGONADISM MARKET KEY FINDINGS

• By drug therapy, gonadotropin and
  gonadotropin-releasing hormones therapy segment
  is projected to grow at the highest CAGR of 8.9
  during the forecast period.
• Pituitary disorders segment is expected to grow
  at the CAGR of 3.2.
• Injectables accounted for nearly half of the
  market share in 2015.
• North America accounted for majority of the share
  (more than three-fourths) in 2015, and is
  expected to remain dominant throughout the
  forecast period.
• U.S. accounted for the majority share in the
  North American market in 2015, and the Mexican
  market is expected to grow at the highest CAGR of
  6.7.

8
 
KEY PLAYERS IN INDUSTRY

• AbbVie Inc.
• Allergan plc
• AstraZeneca plc
• Bayer AG
• Eli Lilly and Company Ltd.
• Endo International plc
• Merck Co., Inc.
• Ferring Holding S.A.
• Finox Biotech
• IBSA Institut Biochimque SA
• Laboratoires Genevrier
• Teva Pharmaceutical Industries Ltd.
• Download Sample Report
• https//www.alliedmarketresearch.com/request-free-
  sample/1874

9
 
MALE HYPOGONADISM MARKET SEGMENTATION
10
 
MALE HYPOGONADISM MARKET BY GEOGRAPHY
North America Europe Asia-Pacific LAMEA
11
 
 
Thank You! For More Details
Visit us at
https//www.alliedmarketresearch.com/male-hypogona
dism-market
Follow Us On